Simon Baldacci

883 total citations
24 papers, 364 citations indexed

About

Simon Baldacci is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Simon Baldacci has authored 24 papers receiving a total of 364 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 8 papers in Molecular Biology. Recurrent topics in Simon Baldacci's work include Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (6 papers) and Liver physiology and pathology (5 papers). Simon Baldacci is often cited by papers focused on Lung Cancer Treatments and Mutations (18 papers), Colorectal Cancer Treatments and Studies (6 papers) and Liver physiology and pathology (5 papers). Simon Baldacci collaborates with scholars based in France, United States and Italy. Simon Baldacci's co-authors include Alexis B. Cortot, Zoulika Kherrouche, David Tulasne, Marie‐Christine Copin, Philippe Jamme, Marie Wislez, Alessandro Furlan, V. Grégoire, Fabienne Escande and Matthieu Jamme and has published in prestigious journals such as Journal of Clinical Oncology, JNCI Journal of the National Cancer Institute and Oncogene.

In The Last Decade

Simon Baldacci

20 papers receiving 363 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Simon Baldacci France 10 244 145 139 107 60 24 364
Philippe Jamme France 9 149 0.6× 110 0.8× 106 0.8× 84 0.8× 45 0.8× 22 256
Xuejing Aimee Wang United States 8 161 0.7× 126 0.9× 131 0.9× 116 1.1× 36 0.6× 15 294
Shiaowen David Hsu United States 10 122 0.5× 181 1.2× 102 0.7× 66 0.6× 46 0.8× 37 313
Yau H. Yu Hong Kong 2 277 1.1× 164 1.1× 104 0.7× 83 0.8× 66 1.1× 2 331
Sai F. Yeung Hong Kong 4 330 1.4× 192 1.3× 140 1.0× 96 0.9× 85 1.4× 4 412
Wing P. Chak Hong Kong 4 292 1.2× 181 1.2× 253 1.8× 83 0.8× 150 2.5× 5 522
Soheil Yala United States 4 103 0.4× 119 0.8× 171 1.2× 98 0.9× 41 0.7× 6 288
Eisuke Kurihara Japan 8 113 0.5× 148 1.0× 110 0.8× 38 0.4× 48 0.8× 12 271
Karin Berghoff Germany 8 123 0.5× 134 0.9× 120 0.9× 69 0.6× 26 0.4× 28 277
Arsène‐Bienvenu Loembé United Kingdom 9 100 0.4× 196 1.4× 168 1.2× 88 0.8× 33 0.6× 15 377

Countries citing papers authored by Simon Baldacci

Since Specialization
Citations

This map shows the geographic impact of Simon Baldacci's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Simon Baldacci with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Simon Baldacci more than expected).

Fields of papers citing papers by Simon Baldacci

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Simon Baldacci. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Simon Baldacci. The network helps show where Simon Baldacci may publish in the future.

Co-authorship network of co-authors of Simon Baldacci

This figure shows the co-authorship network connecting the top 25 collaborators of Simon Baldacci. A scholar is included among the top collaborators of Simon Baldacci based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Simon Baldacci. Simon Baldacci is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Mazières, Julien, Florian Guisier, Marion Ferreira, et al.. (2023). Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC). Lung Cancer. 186. 107393–107393. 1 indexed citations
3.
Béhal, Hélène, Loïc Lebellec, Simon Baldacci, et al.. (2021). Does bevacizumab increase joint pain in patients with cancer? Results of the prospective observational BEVARTHRALGIA study. Cancer Chemotherapy and Pharmacology. 87(4). 533–541. 3 indexed citations
4.
Mazières, Julien, Florian Guisier, M. Ferreira, et al.. (2021). 1341P NRAS mutated non-small cell lung cancer (NSCLC) patients: Characteristics and outcomes. Annals of Oncology. 32. S1023–S1024. 1 indexed citations
5.
Girard, Nicolas, M. Duruisseaux, Virginie Avrillon, et al.. (2020). 1349P Lorlatinib for advanced ROS1+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S865–S865. 1 indexed citations
6.
Baldacci, Simon, V. Grégoire, Enrico Patrucco, et al.. (2020). Complete and prolonged response to anti-PD1 therapy in an ALK rearranged lung adenocarcinoma. Lung Cancer. 146. 366–369. 11 indexed citations
7.
Baldacci, Simon, Benjamin Besse, Virginie Avrillon, et al.. (2020). 1303P Lorlatinib for advanced ALK+ non-small cell lung cancer (NSCLC): Efficacy and safety data from IFCT-1803 LORLATU expanded access program (EAP) cohort. Annals of Oncology. 31. S843–S843. 1 indexed citations
8.
Jamme, Philippe, Marie Fernandes, Marie‐Christine Copin, et al.. (2020). Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations. Journal of Thoracic Oncology. 15(5). 741–751. 60 indexed citations
9.
Baldacci, Simon, Virginie Avrillon, Benjamin Besse, et al.. (2020). Lorlatinib for advanced ALK and ROS1+ non-small cell lung cancer (NSCLC): Efficacy and treatment sequences in the IFCT-1803 LORLATU expanded access program (EAP) cohort.. Journal of Clinical Oncology. 38(15_suppl). 9615–9615. 3 indexed citations
10.
Baldacci, Simon, Martin Figeac, Martine Antoine, et al.. (2019). High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study. Journal of Thoracic Oncology. 15(1). 120–124. 16 indexed citations
11.
Jamme, Philippe, Radj Gervais, Éric Dansin, et al.. (2019). Relevance of Detection of Mechanisms of Resistance to ALK Inhibitors in ALK-Rearranged NSCLC in Routine Practice. Clinical Lung Cancer. 20(4). 297–304.e1. 14 indexed citations
12.
Baldacci, Simon, Martin Figeac, Martine Antoine, et al.. (2019). P2.14-53 High MET Overexpression Does Not Predict the Presence of MET Exon 14 Splice Mutations in NSCLC: Results from the IFCT Predict.amm Study. Journal of Thoracic Oncology. 14(10). S851–S851. 2 indexed citations
13.
Leprêtre, Frédéric, Fabienne Escande, Zoulika Kherrouche, et al.. (2018). Optimization of Routine Testing for MET Exon 14 Splice Site Mutations in NSCLC Patients. Journal of Thoracic Oncology. 13(12). 1873–1883. 27 indexed citations
14.
Baldacci, Simon, Zoulika Kherrouche, Marie Wislez, et al.. (2018). Les mutations des sites d’épissage de l’exon 14 de MET. Une nouvelle opportunité thérapeutique dans le cancer du poumon. Revue des Maladies Respiratoires. 35(8). 796–812. 6 indexed citations
15.
Baldacci, Simon, Zoulika Kherrouche, Vincent Cockenpot, et al.. (2018). MET amplification increases the metastatic spread of EGFR-mutated NSCLC. Lung Cancer. 125. 57–67. 26 indexed citations
16.
Kherrouche, Zoulika, Simon Baldacci, Philippe Jamme, et al.. (2018). The multiple paths towards MET receptor addiction in cancer. Oncogene. 37(24). 3200–3215. 42 indexed citations
17.
Collet, Guillaume, et al.. (2017). MA10.10 [18F]-FDG-PET/CT Early Response to Nivolumab in NSCLC. Journal of Thoracic Oncology. 12(1). S402–S402. 1 indexed citations
18.
Baldacci, Simon, Julien Mazières, Pascale Tomasini, et al.. (2017). P3.02b-051 Outcome of Advanced EGFR-Mutated NSCLC Patients with MET-Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study. Journal of Thoracic Oncology. 12(1). S1219–S1220.
19.
Cortot, Alexis B., Zoulika Kherrouche, Marie Wislez, et al.. (2016). Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers. JNCI Journal of the National Cancer Institute. 109(5). 80 indexed citations
20.
Scherpereel, Arnaud, Bogdan Grigoriu, Marc Noppen, et al.. (2013). Defect in recruiting effector memory CD8+T-cells in malignant pleural effusions compared to normal pleural fluid. BMC Cancer. 13(1). 324–324. 36 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Philippe Jamme Breakdown of academic impact, for papers by Xuejing Aimee Wang Breakdown of academic impact, for papers by Shiaowen David Hsu Breakdown of academic impact, for papers by Yau H. Yu Breakdown of academic impact, for papers by Sai F. Yeung Breakdown of academic impact, for papers by Wing P. Chak Breakdown of academic impact, for papers by Soheil Yala Breakdown of academic impact, for papers by Eisuke Kurihara Breakdown of academic impact, for papers by Karin Berghoff Breakdown of academic impact, for papers by Arsène‐Bienvenu Loembé
Rankless by CCL
2026